Brokers Issue Forecasts for Pfizer's Q2 Earnings (NYSE:PFE)

Pfizer Inc. (NYSE:PFE - Free Report) - Zacks Research lowered their Q2 2026 EPS estimates for Pfizer in a research report issued on Thursday, March 20th. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will earn $0.57 per share for the quarter, down from their previous forecast of $0.58. The consensus estimate for Pfizer's current full-year earnings is $2.95 per share. Zacks Research also issued estimates for Pfizer's FY2027 earnings at $2.96 EPS.

Several other research analysts have also recently issued reports on the company. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Bank of America reissued a "neutral" rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Citigroup dropped their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Finally, Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $31.92.

Remove Ads

Pfizer Stock Performance

PFE stock traded down $0.16 during midday trading on Monday, reaching $25.05. The stock had a trading volume of 51,260,038 shares, compared to its average volume of 36,817,956. The firm has a fifty day simple moving average of $26.09 and a two-hundred day simple moving average of $26.97. Pfizer has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market cap of $142.08 billion, a PE ratio of 17.77, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter last year, the company posted $0.10 earnings per share. The business's quarterly revenue was up 24.7% on a year-over-year basis.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 0.06% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Pfizer

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in shares of Pfizer by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company's stock valued at $13,756,738,000 after purchasing an additional 2,285,276 shares during the period. State Street Corp boosted its holdings in Pfizer by 1.2% in the 3rd quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company's stock worth $8,405,930,000 after buying an additional 3,405,539 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after buying an additional 25,315,159 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Pfizer by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company's stock valued at $3,190,131,000 after acquiring an additional 2,923,537 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Pfizer in the fourth quarter valued at approximately $2,328,986,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.